Calcitonin and Carcinoembryonic Antigen Doubling Times As Prognostic Factors in Medullary Thyroid Carcinoma: a Structured Meta-analysis
Overview
Authors
Affiliations
Context: In the management of patients with medullary thyroid carcinoma (MTC), calcitonin doubling time (dt) has gained interest as an independent predictor of recurrence and survival.
Objective: To perform a structured meta-analysis of the diagnostic value of calcitonin dt, carcinoembryonic antigen (CEA) dt and the combination and to define dt strata with the highest predictive power. Design The study was a meta-analysis using individual data.
Methods: Ten studies containing data on the post-operative kinetics of tumour marker(s) and (recurrence free) survival were included.
Results: Calcitonin- and CEA-dt are significant indicators for survival (hazard ratios (HR) 21.52 respectively infinite for dt 0-1 year compared to dt >1 year) and recurrence (HR 5.33 respectively 6.80 for dt 0-1 year compared to dt >1 year). The highest predictive power was found for the dt classification 0-1 year vs. >1 year. CEA dt has a higher predictive value than calcitonin dt in the subgroup of patients for which both parameters were available.
Conclusion: The dts of both calcitonin and CEA are strong prognostic indicators for MTC recurrence and death. CEA dt has a higher predictive value than calcitonin dt and therefore measuring both tumour markers is essential for proper risk stratification.
Jager E, van Hemel B, Rutgers B, Zandee W, Jansen L, Kruijff S Cancers (Basel). 2025; 17(5).
PMID: 40075585 PMC: 11899120. DOI: 10.3390/cancers17050737.
Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
Guo F, Fu G, Li F, Hua Y, Wang Z, Zheng X World J Surg Oncol. 2024; 22(1):121.
PMID: 38711029 PMC: 11071271. DOI: 10.1186/s12957-024-03397-3.
Reti Z, Tabak A, Garami M, Kalina I, Kiss G, Sapi Z JCO Precis Oncol. 2024; 8:e2300675.
PMID: 38709988 PMC: 11161236. DOI: 10.1200/PO.23.00675.
Guo F, Li L, Gu P, Zhang G, Ruan X, Zhao J Heliyon. 2024; 10(8):e29857.
PMID: 38681571 PMC: 11046226. DOI: 10.1016/j.heliyon.2024.e29857.
Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.
Liu S, Zhao H, Li X Cancer Manag Res. 2024; 16:299-310.
PMID: 38617188 PMC: 11011642. DOI: 10.2147/CMAR.S440477.